Edap TMS asks FDA to OK Ablatherm prostate treatment

February 1, 2013 by MassDevice staff

French medical device company Edap TMS asks the FDA for pre-market approval of its Ablatherm treatment for prostate cancer.

Edap TMS

EDAP (NSDQ:EDAP) said it filed for pre-market approval of its Ablatherm-HIFU prostate cancer treatment from the FDA.

The Lyon, France-based medical device company said the high-intensity focused ultrasound device is designed to treat low-risk, localized prostate cancer. The PMA submission is backed by data from Edap's Enlight study, according to a press release.

"We have clearly seen a paradigm shift in prostate cancer, as patients are diagnosed earlier than ever before. Low-risk patients need a middle ground between radical treatment, which is often overly-aggressive, and the anxiety of 'watchful waiting.' Ablatherm-HIFU is well-positioned to address this unmet medical need by providing a unique non-invasive and fully robotic treatment option," CEO Marc Oczachowski said in prepared remarks.

Sign up to get our free newsletters delivered straight to your inbox

The Ablatherm-HIFU device is already approved in the European Union, South Korea, Canada, Australia, South Africa, New Zealand, the Philippines, Taiwan, Mexico, Argentina, Brazil and Russia, according to the release.


Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp